Latest Research in HIV/AIDS drug development and treatment
27 research papers · 2026 median publication year
Top Research Topics in HIV/AIDS drug development and treatment
- HIV/AIDS drug development and treatment — 16 papers
- HIV Research and Treatment — 5 papers
- HIV/AIDS Research and Interventions — 2 papers
- HIV-related health complications and treatments — 2 papers
- Respiratory viral infections research — 1 papers
- Viral-associated cancers and disorders — 1 papers
Highest-Cited Papers
- Exhaustive Search Outperforms a Genetic Algorithm for Formulary-Constrained Antiretroviral Regimen Selection
- Virologic, Lipid, Renal and Hepatic Laboratory Outcomes After Switching to Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate in Treatment-Experienced People with HIV: Real-World Evidence from the SHINe-SHIC Cohort
- Quality of life among older adults with HIV after switching to bictegravir‐based three‐drug or dolutegravir‐based two‐drug regimens
- Virological effectiveness and metabolic/laboratory outcome profile of INSTI-based versus NNRTI-based initial ART in Shandong, China: a province-wide real-world cohort study
- Determinants of rapid antiretroviral therapy initiation and its longitudinal clinical outcomes among people living with HIV in China: a single-center retrospective cohort study
- PATTERNS OF WHO HIV DRUG RESISTANCE EARLY WARNING INDICATOR PERFORMANCE ACROSS ART PROGRAMS IN SUB-SAHARAN AFRICA: A SYSTEMATIC REVIEW
- Genotype-guided antiretroviral therapy outcomes in routine clinical practice: a retrospective study of HIV viral load suppression at 6 and 12 months in Uganda
- Broadly neutralizing antibodies in adult males living with HIV undergoing analytical treatment interruption: secondary and exploratory outcomes of the phase II randomized controlled RIO trial
- Virological and metabolic outcomes after switching to dolutegravir or rilpivirine in virologically suppressed adults with HIV in Thailand: an open-label, randomised, controlled, non-inferiority trial
- Distribution of plasma tenofovir trough concentrations and associated factors in Japanese patients with HIV-1 receiving bictegravir/emtricitabine/tenofovir alafenamide
- Growth Outcomes After 48 Weeks of Dolutegravir in Children and Adolescents with HIV-1 in IMPAACT P1093 and IMPAACT 2019
- Impact of Fostemsavir in Individuals with Multidrug-Resistant HIV-1, Stratified by Baseline Viral Load
- Tolerability and Virologic Outcomes after Transition from Long-Acting Injectable ART to Oral ART
- Long‐acting cabotegravir and rilpivirine in people with HIV and cancer: Virological eligibility and DDI considerations
- PERFORMANCE OF HIV DRUG RESISTANCE EARLY WARNING INDICATORS AND ASSOCIATED PROGRAM FACTORS IN LESOTHO DURING THE DOLUTEGRAVIR ERA
- PERFORMANCE OF HIV DRUG RESISTANCE EARLY WARNING INDICATORS AND ASSOCIATED PROGRAM FACTORS IN LESOTHO DURING THE DOLUTEGRAVIR ERA
- Buying Time: T cells and Delayed HIV Rebound After Treatment Interruption
- Evaluating the combination of bictegravir and lenacapavir as a single tablet option for HIV
- A REVIEW ON A MIRACLE DRUG "DOLUTEGRAVIR" IN A RURAL TERTIARY HOSPITAL
- A REVIEW ON A MIRACLE DRUG "DOLUTEGRAVIR" IN A RURAL TERTIARY HOSPITAL